← Novo Nordisk AS
What podcasts say about Novo Nordisk AS
Every statement, with the speaker, the exact quote and the moment it was said.
What experts have said about Novo Nordisk AS
6 statements · 6 negative
The Nanexa deal is unlikely to trigger Novo Nordisk’s price in the short term.
“it's unlikely to be a short-term trigger for their price”
Open the episode · UBS Rises, Novo Climbs, HelloFresh PlummetsListen at 2:53
Novo Nordisk’s weight-loss pill missed expectations
“The weight loss pill did not manage to beat expectations.”
Open the episode · Novo Nordisk Drops, Puma Down, Trainline RisesListen at 1:43
Several factors may complicate Novo Nordisk’s outlook.
“there's going to be some, perhaps some things kind of complicating the outlook for Novo”
Open the episode · Novo Nordisk Drops, Next Jumps, Infineon FallsListen at 1:42
Novo Nordisk has experienced recent clinical-trial setbacks.
“there's been recent trial setbacks as well for Novo”
Open the episode · Novo Nordisk Drops, Next Jumps, Infineon FallsListen at 2:07
Novo Nordisk’s experimental drug failed to reduce cardiovascular risk in a large study.
“one of its experimental drugs failed to reduce the risk of heart disease and strokes in a large study”
Open the episode · Apple Tumbles, Amazon Soars, Novo Nordisk Slides as New Drug Fails in Closely Watched Heart, Stroke Study On this episode of Stock Movers:Listen at 3:01
The failed drug study harms Novo Nordisk’s diversification effort beyond obesity and diabetes.
“This is a real blow for this company as it's trying to diversify away from obesity and the diabetes space where it's been the pioneer.”
Open the episode · Apple Slides Most Since 2025, Amazon Soars, NovoListen at 4:51
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.